Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 5/20 | 0.49 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.49 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.49 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.49 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.49 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.49 |
| ▸ | CES2 | O00748 | 3/20 | 0.46 |
| ▸ | CES1 | P23141 | 3/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30446775 | 1.00 | PSEN1 (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL31074203 | 1.00 | PSEN1 (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL31074208 | 0.85 | CES2 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL20943341 | 0.85 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL20943342 | 0.85 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3185608 | 0.85 | CES2 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL22618975 | 0.85 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30446762 | 0.85 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL20021547 | 0.84 | CES2 (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL31074204 | 0.83 | PSEN1 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111434671-B | Liver-specific AMPK agonist and preparation method and application thereof | 凯思凯迪（上海）医药科技有限公司 | 2023-07-11 | — | — | CN | disclosed |
| CN-111434671-A | Liver specificity AMPK agonist and preparation method and application thereof | 凯思凯迪（上海）医药科技有限公司 | 2020-07-21 | — | — | CN | disclosed |
| CN-110914271-A | Bicyclic ketone compounds and methods of use thereof | 豪夫迈·罗氏有限公司 | 2020-03-24 | — | — | CN | disclosed |
| US-7666855-B2 | 2′-C-methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090131370-A1 | Novel Nucleoside Derivatives | METABASIS THERAPEUTICS , INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MERCK SHARP & DOHME CORP. | 2009-05-07 | — | — | US | disclosed |
| EP-1915053-A2 | NOVEL 2'-C-METHYL AND 4'-C-METHYL NUCLEOSIDE DERIVATIVES | Merck & Co., Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| EP-1905778-A2 | Novel 2'-C-methyl nucleoside derivatives | Metabasis Therapeutics, Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20070179114-A1 | Novel 2'-C methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| EP-1781101-A2 | NOVEL NUCLEOSIDE DERIVATIVES | Metabasis Therapeutics, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20070042989-A1 | Novel 2'-C-methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007022073-A2 | NOVEL 2'-C-METHYL AND 4'-C-METHYL NUCLEOSIDE DERIVATIVES | MERCK & CO., INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| EP-1720556-A2 | NOVEL 2'-C-METHYL NUCLEOSIDE DERIVATIVES | Merck & Co., Inc. (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2006033709-A2 | NOVEL NUCLEOSIDE DERIVATIVES | METABASIS THERAPEUTICS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2005084192-A2 | NOVEL 2’-C-METHYL NUCLEOSIDE DERIVATIVES | MERCK & CO., INC. (US) | 2005-09-15 | — | — | WO | disclosed |
| US-20050182252-A1 | Hepatitis C viral infection; 2'-C-beta-methyl-7-deazaadenosine; trans-4-(aryl)-2-(4-nitrophenoxy)-2-oxo-1,3,2-dioxaphosphorinanes | METABASIS THERAPEUTICS, INC. | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131370-A1 | Novel Nucleoside Derivatives | SLC29A1, SLC29A2, PNP | PSEN1 2500/4885PSEN2 2592/4885APH1B 3126/4885 |
| US-20050182252-A1 | Hepatitis C viral infection; 2'-C-beta-methyl-7-deazaadenosine; trans-4-(aryl)-2-(4-nitrophenoxy)-2-oxo-1,3,2-dioxaphosphorinanes | MTAP, NT5C3B, ADAR | PSEN1 3922/4885PSEN2 4464/4885APH1B 3119/4885 |
| US-20070042989-A1 | Novel 2'-C-methyl nucleoside derivatives | NSUN2, NT5C3B, MTAP | PSEN1 3762/4885PSEN2 3796/4885APH1B 2665/4885 |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MTAP, NT5C3B, NSUN2 | PSEN1 4395/4885PSEN2 4195/4885APH1B 3514/4885 |
| US-20070179114-A1 | Novel 2'-C methyl nucleoside derivatives | NSUN2, NT5C3B, MTAP | PSEN1 3891/4885PSEN2 3812/4885APH1B 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.